PDF
VibroSense Meter® II Receives Regulatory Approval in Turkey
VibroSense Dynamics AB (publ) announces today that VibroSense Meter® II has received regulatory approval in Turkey through MDR registration completed by the company's Turkish distributor Alpmed Tibbi Cihazlar. The approval gives Alpmed the green light to begin commercial sales of the instrument in the Turkish market, with full support from VibroSense Dynamics.
Turkey is one of Europe's and the Middle East's most dynamic healthcare markets, with a population of over 85 million and a rapidly growing diabetes population. The country has an increasing focus on neurological diagnostics and occupational health, creating strong demand for objective nerve function measurement. VibroSense Dynamics will support Alpmed in the market launch and establishment through training, technical support and clinical collaboration. Early interest has already been noted from leading academic institutions
"We are pleased that Alpmed has completed the registration process and that we can now take the next step together in the Turkish market. Turkey is a large and dynamic market where the need for early and objective nerve diagnostics is significant, and we look forward to supporting Alpmed in introducing VibroSense Meter® II to Turkish clinicians and researchers", says Toni Speidel, CEO of VibroSense Dynamics AB.
For more information, please contact:
Toni Speidel, CEO
VibroSense Dynamics AB (publ)
Phone: +46 40 88 026
Email: info@vibrosense.com
Website: www.vibrosense.com
"The new Gold Standard for reliable
detection of nerve damage"
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical devices and services to facilitate diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to perceive vibrations applied to the skin at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers.
Our vision that the company's products shall become a standard tool in all neurological examinations, to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.